Clinical Research & TrialsCBL-514 reduced abdominal subcutaneous fat in randomized phase 2 trials and showed an early visceral-fat signal, but it is not yet a proven obesity or weight-loss treatment.
Read the Full Bite →
Clinical Research & TrialsGLP-1 drugs have been linked to hair loss, but the absolute risk is small and rapid weight loss may be part of the explanation. Here is what the evidence shows.
Read the Full Bite →
Cell & Molecular BiologyGLP-1 links the gut, pancreas, stomach, and brain. Here is how the pathway controls blood sugar, appetite, gastric emptying, and weight.
Read the Full Bite →
Clinical Research & TrialsOral and injectable Wegovy use the same drug but differ in dosing, absorption, and convenience. Here is how the evidence compares for obesity treatment.
Read the Full Bite →
Cardiovascular HealthHepcidin controls how iron moves through the body. In polycythemia vera, that makes iron restriction a way to reduce excess red blood cell production.
Read the Full Bite →
Cancer & OncologyOral SERDs degrade the estrogen receptor and are changing treatment for ESR1-mutated breast cancer. Here is how they differ from aromatase inhibitors, tamoxifen, and fulvestrant.
Read the Full Bite →
Clinical Research & TrialsBeyfortus dosing changes by weight and RSV season. Here is when nirsevimab is given as 50 mg, 100 mg, or 200 mg and who is eligible.
Read the Full Bite →
Cell & Molecular BiologyTYK2 and JAK1 help cytokines activate the JAK-STAT pathway. Here is how selective inhibition differs from broader JAK blockade and why it matters in autoimmune disease.
Read the Full Bite →
Cancer & OncologyCDK4/6 inhibitors slow HR-positive breast cancer by blocking a cell-cycle checkpoint. Here is how palbociclib, ribociclib, and abemaciclib work and how resistance develops.
Read the Full Bite →
Diabetes & MetabolismSemaglutide and tirzepatide withdrawal trials show substantial weight regain after treatment stops. Here is what the evidence says and what it does not.
Read the Full Bite →
Infectious DiseaseNirsevimab and clesrovimab both prevent severe infant RSV disease, but they bind different viral sites, use different dosing schemes, and were not tested head to head.
Read the Full Bite →
Diabetes & MetabolismNausea and other gastrointestinal symptoms are common with GLP-1-based medicines, while pancreatitis, gallbladder disease, dehydration, and other serious risks are less frequent.
Read the Full Bite →
Diabetes & MetabolismGIP and GLP-1 both increase meal-stimulated insulin secretion, but their biology differs. Tirzepatide activates both receptors, creating a distinct dual-incretin drug profile.
Read the Full Bite →
Aging & LongevityIn a Nature study, semaglutide extended median lifespan by 92 days in older female mice and reproduced many effects of calorie restriction.
Read the Full Bite →
PharmacologyGLP-1 drugs now treat far more than diabetes and weight. A clear guide to how they work, which are approved, how well they work, and what is coming next.
Read the Full Bite →
PharmacologyThe blockbuster class started with diabetes and keeps finding new frontiers.
Read the Full Bite →